Aptima HPV Test – Aiming at risk
Aptima HPV Test for high risk types and Aptima HPV 16 18/45 detect the presence of an active HPV infection, which may cause cervical cancer. Almost all women and men will come in contact with the virus at some point in their life. However, very few will suffer from the infection or will have cancer 1. Aptima HPV Test detects oncogenes Ε6/Ε7 of the oncogenic mRNA HPV types 2. The expression of mRNA proteins Ε6/Ε7 indicates that the virus infection will lead to the disease 2,3.
Since HPV DNA levels may be reduced while the infection becomes cancer, some HPV DNA tests give false negative results in more than 10% of serious cervical lesions 4.
― Aptima HPV test design
Aptima HPV Test, by detecting areas Ε6/Ε7 of the virus mRNA aims at the oncogenic action of the virus 5.
Tests aiming at L1 virus area, aim only at one area, which is not a necessary factor to the progress of the disease and which may disappear during the virus integration 9. There is up to 10-15% risk that some serious cases of the disease are not detected, if a test based only on L1 area detection is used 6-8.
― During Integration L1 area may be deleted
Aptima HPV Test is as sensitive as an HPV DNA Test. High sensitivity minimizes false negative results. At the same moment, Aptima HPV Test offers high specificity. In other words, it reduces false positive results, therefore, meaningless therapeutic interventions. Aptima HPV Test gave 24% less false negative results than a HPV DNA test 5.
1 Genital HPV Infection – CDC Fact Sheet. http://www.cdc.gv./std/hpv/hpv-factsheet-march-2014-press.pdf.Published 2014. Accessed August 24, 2015.
2 Tinelli A, et al. HPV viral activity by mRNA HPV molecular analysis to screen the transforming infections in precancer cervical lesions. Curr Pharm Biotechnol. 2009;10(8):767-771
3 Cuschieri K, et al. Human Papillomavirus Type Specific DNA and RNA Persistence-Implications for Cervical Disease Progression and Monitoring. J Med Virol. 2004;73(1):65-70.
4 Wright C, et al. The ATHENA human papillomavirus study: design, methods & baseline results. Am J Obstet Gynecol. 2012;206(1):46.e1-46.e11 (Study included cobas® HPV, Hybrid Capture® 2 assay)
5 Aptima HPV Assay (package insert, AW-11141-001 Rev 003 (EN)), San Diego, CA; Hologic, Inc., 2015. Table ≠22.
6 De Sanjose, Lancet Oncol. 2010;11:1048-56.
7 Wheeler CM, et al. J Natl Cancer Institute 2009;101:475-487
8 Coutlee F, et al. J.Med.Virol. 2011;83:1034-1041
9 Morris, Clin Chem Lab Med 2005; 43(11):1171-1177